The article talks about things like determining height, but that's a silly thing to focus on because it is enormously complex. The things to focus on are the single gene alterations that have large benefits, and that can be done either now or very soon in humans, with low cost and high reliability.
What can be done now or soon includes:
a) additional muscle, via myostatin or follistatin, with human trials on non-genetic manipulation of these proteins already showing positive results, at least one human recipient of gene therapy, several natural human mutants, and years of heavily muscled animal studies.
b) telomerase gene therapy, if you're willing to take the cancer risk. It lowers cancer incidence in mice, counterintuitively, but mice have very different telomere dynamics from humans. Also at least one human recipient.
c) extra lysosomal receptors, which has been shown to restore youthful liver function in rodents.
d) and fifty or more other genes with varying degrees of support for things ranging from a halving of post-stroke ischemic damage to lower pace of generation of amyloid to a whole range of other things that sound worth having.
e) and the hundreds of single-gene mutations that cause serious disease. Fixing those.
This is the stuff that will be rolling into action over the next decade. It is so cheap that it will absolutely go the way of early stem cell treatments with widespread availability via medical tourism. That is where entrepreurs can make a real impact The skills needed to build CRISPR therapies are just as widespread as those needed to run a stem cell clinic - and overlap to a considerable degree, so that a large fraction of the existing stem cell centers are quite capable of adding gene therapies to their offerings given a few years of organization.